Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Commercial Officer

Sr. VP, Chief Medical Officer

Chair, President & CEO

SR VP & Chief Fin. Officer

Senior VP, Chief Bus. Officer

Executive VP & CFO

Chairman, President & CEO

Senior VP & CFO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical ne...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-09-22	Premium	bought	Premium	Premium	Premium	-
2023-01-19	Premium	acquired	Premium	Premium	Premium	Chief Commercial Officer
2023-01-19	Premium	acquired	Premium	Premium	Premium	Sr. VP, Chief Medical Officer
2023-01-19	Premium	acquired	Premium	Premium	Premium	Chair, President & CEO
2023-01-19	Premium	acquired	Premium	Premium	Premium	SR VP & Chief Fin. Officer
2022-09-19	Premium	bought	Premium	Premium	Premium	Chair, President & CEO
2022-09-19	Premium	bought	Premium	Premium	Premium	SR VP & Chief Fin. Officer
2022-06-06	Premium	bought	Premium	Premium	Premium	Chair, President & CEO
2021-12-20	Premium	bought	Premium	Premium	Premium	-
2021-12-16	Premium	bought	Premium	Premium	Premium	-
2021-12-16	Premium	bought	Premium	Premium	Premium	Chair, President & CEO
2021-12-15	Premium	bought	Premium	Premium	Premium	-
2021-12-15	Premium	bought	Premium	Premium	Premium	Chair, President & CEO
2021-11-26	Premium	bought	Premium	Premium	Premium	Chair, President & CEO
2021-11-19	Premium	acquired	Premium	Premium	Premium	-
2021-11-19	Premium	bought	Premium	Premium	Premium	Sr. VP, Chief Medical Officer
2021-08-05	Premium	sold	Premium	Premium	Premium	-
2021-08-03	Premium	bought	Premium	Premium	Premium	-
2021-07-02	Premium	bought	Premium	Premium	Premium	Chair, President & CEO
2021-06-22	Premium	sold	Premium	Premium	Premium	-
2021-06-21	Premium	sold	Premium	Premium	Premium	-
2020-12-22	Premium	acquired	Premium	Premium	Premium	-
2020-12-22	Premium	sold	Premium	Premium	Premium	-
2020-07-10	Premium	sold	Premium	Premium	Premium	Senior VP, Chief Bus. Officer
2020-07-10	Premium	sold	Premium	Premium	Premium	Chair, President & CEO

APTO - Aptose Biosciences Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for APTO